At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 220 target
Drug / intervention
Intrathecal pemetrexeddrug
Likely dose
Intrathecal pemetrexed 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Investigate the Efficacy and Resistance Mechanisms of Intrathecal Pemetrexed in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Harboring Oncogenic Mutations With Leptomeningeal Metastases
In Brief
A Phase 2 clinical trial evaluating Intrathecal pemetrexed for Non-Small Cell Lung Cancer. Currently recruiting, targeting 220 participants across 1 site.
Detailed Summary
This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina
CollaboratorsHunan Cancer Hospital
Timeline
Phase 2Recruiting
202520262027
Enrollment StartMay 2024
First PostedJun 2024
TodayJul 2026
Primary CompletionDec 2026
Study CompletionApr 2027
First PostedJun 4, 2024
Enrollment StartMay 1, 2024
Primary CompletionDec 31, 2026
Study CompletionApr 30, 2027
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 2.1 years agoPrimary completion in 6 months
Interventions
Intrathecal pemetrexeddrug
Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.